MR成像与CT鉴别遗传性与非遗传性头颈部副神经节瘤
单中心回顾性研究纳入40例患者共48个头颈部副神经节瘤,评估ADC值及CT/MR肿瘤特征能否鉴别SDH突变阳性与阴性肿瘤。结果显示SDH突变阳性组的ADCmean、ADCmaximum及其归一化值均显著低于突变阴性组,而ADCminimum及常规影像特征无统计学差异。
要点
- SDH突变阳性副神经节瘤的ADCmean和ADCmaximum显著低于突变阴性者。
- 以延髓ADC归一化后的ADC值同样在两组间有显著差异。
- ADCminimum及CT/MR常规肿瘤特征无法鉴别SDH突变状态。
关键影像表现/征象
- ADCminimum、归一化ADCminimum及CT/MR肿瘤特征在两组间无统计学意义。
诊断标准与关键数值
- ADCminimum、归一化ADCminimum及常规影像特征不能鉴别SDH突变状态。
临床应用与阅片要点
- 在头颈部副神经节瘤MR报告中,可测量ADCmean和ADCmaximum并计算与延髓ADC的归一化值,辅助提示SDH突变状态。
- ADCminimum和常规CT/MR特征(如大小、边界等)对鉴别SDH突变价值有限,不应单独依赖。
- 需注意本研究为单中心回顾性设计,ADC阈值尚未确立,不能直接用于临床决策。
局限性
- 单中心回顾性研究,样本量较小(40例患者/48个肿瘤)。
- 未报告ADC诊断的敏感度、特异度、AUC及最佳阈值。
- 未报告观察者间一致性及CT/MR具体序列参数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Head and neck paragangliomas have been reported to be associated with mutations of the succinate dehydrogenase enzyme family. The aim of this study was to assess whether radiologic features could differentiate between paragangliomas in the head and neck positive and negative for the succinate dehydrogenase mutation.
MATERIALS AND METHODS: This single-center retrospective review from January 2015 to January 2020 included 40 patients with 48 paragangliomas (30 tumors positive for succinate dehydrogenase mutation in 23 patients and 18 tumors negative for the succinate dehydrogenase mutation in 17 patients). ADC values and tumor characteristics on CT and MR imaging were evaluated by 2 radiologists. Differences between the 2 cohorts in the diagnostic performance of ADC and normalized ADC (ratio to ADC in the medulla oblongata) values were evaluated using the independent samples t test. P < .05 was considered significant.
RESULTS: ADCmean (1.07 [SD, 0.25]/1.04 [SD, 0.12] versus 1.31 [SD, 0.16]/1.30 [SD, 0.20]× 10-3 mm2/s by radiologists 1 and 2; P < .001), ADCmaximum (1.49 [SD, 0.27]/1.49 [SD, 0.20] versus 2.01 [SD, 0.16]/1.87 [SD, 0.20] × 10-3 mm2/s; P < .001), normalized ADCmean (1.40 [SD, 0.33]/1.37 [SD, 0.16] versus 1.73 [SD, 0.22]/1.74 [SD, 0.27]; P < .001), and normalized ADCmaximum (1.95 [SD, 0.37]/1.97 [SD, 0.27] versus 2.64 [SD, 0.22]/2.48 [SD, 0.28]; P < .001) were significantly lower in succinate dehydrogenase mutation-positive than mutation-negative tumors. ADCminimum, normalized ADCminimum, and tumor characteristics were not statistically significant.
CONCLUSIONS: ADC is a promising imaging biomarker that can help differentiate succinate dehydrogenase mutation-positive from mutation-negative paragangliomas in the head and neck.
引用
- Ota Y, Naganawa S, Kurokawa R, et al. Assessment of MR Imaging and CT in Differentiating Hereditary and Nonhereditary Paragangliomas. AJNR Am J Neuroradiol. 2021. PMID: 33985956. doi:10.3174/ajnr.A7166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。